BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2018

View Archived Issues

PI3Kdelta in autoimmunity

Read More

Ketamine activates opioid system

Read More

Repeat expansions disrupt large-scale genome organization

Read More

HECTD3 negatively regulates host defense against intracellular bacteria by modulation of type I IFN

Read More

Complete response observed in phase I study of ET-140202 in metastatic HCC

Read More

Brain immune cells show multiple sex differences

Read More

TSI initiates phase II study of its novel treatment regimen for ischemic stroke

Read More

Yumanity Therapeutics names first clinical candidate for Parkinson's disease

Read More

MabSpace initiates Chinese phase I trial of MSB-2311, files IND for MSB-0254

Read More

C11orf95-RELA fusion drives ST-ependymoma formation through NF-kappaB and other signaling pathways

Read More

Beta1-integrin promotes endothelial barrier disruption: a new target to prevent vascular leakage

Read More

HAS2 gene linked to the pathogenesis of lower extremity varicose veins

Read More

Combining ACE2 and BNP biomarkers improves risk stratification in patients with aortic stenosis

Read More

Researchers identify FHOD3 as a novel disease-causing gene in hypertrophic cardiomyopathy

Read More

Torrent Pharmaceuticals patents compounds for asthma and COPD

Read More

A*STAR identifies new SMYD3 inhibitors for cancer

Read More

Xenon Pharmaceuticals to develop ezogabine for KCNQ2 epileptic encephalopathy

Read More

Chinese researchers disclose Abeta aggregation inhibitors

Read More

FDA approves Tiglutik oral suspension for the treatment of ALS

Read More

Phase IIa study of Yeliva for cholangiocarcinoma advances to second stage

Read More

Eli Lilly presents AOC3 inhibitors

Read More

Luye initiates phase III trials in China with LY-01005 for prostate cancer

Read More

Atara Biotherapeutics to develop CAR T immunotherapies with Moffitt Cancer Center

Read More

NIH grants supports Hepseros' development of human-on-a-chip technology

Read More

Soleno amends phase III trial protocol for diazoxide choline in Prader-Willi syndrome

Read More

Checkpoint Therapeutics reports promising phase I/II data with CK-101 in EGFR-mutated NSCLC

Read More

Compugen initiates clinical testing of COM-701 in advanced solid tumors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing